BNP Paribas Financial Markets Reduces Position in argenx SE (NASDAQ:ARGX)

BNP Paribas Financial Markets reduced its holdings in argenx SE (NASDAQ:ARGX) by 48.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,292 shares of the company’s stock after selling 4,050 shares during the period. BNP Paribas Financial Markets’ holdings in argenx were worth $2,327,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ARGX. Cetera Advisors LLC purchased a new position in argenx in the 1st quarter worth approximately $419,000. GAMMA Investing LLC lifted its position in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares in the last quarter. Park Avenue Securities LLC boosted its stake in argenx by 7.2% during the second quarter. Park Avenue Securities LLC now owns 1,324 shares of the company’s stock worth $569,000 after buying an additional 89 shares during the last quarter. SG Americas Securities LLC grew its holdings in argenx by 10.4% in the 2nd quarter. SG Americas Securities LLC now owns 2,999 shares of the company’s stock valued at $1,290,000 after buying an additional 283 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its holdings in argenx by 3.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock valued at $737,000 after buying an additional 52 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Guggenheim boosted their price target on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and lifted their target price for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and increased their price target for the company from $515.00 to $650.00 in a research note on Friday, November 1st. Wedbush reaffirmed an “outperform” rating and set a $655.00 price target on shares of argenx in a research report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $617.00 price objective on shares of argenx in a research report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and an average target price of $635.42.

argenx Stock Down 0.5 %

Shares of ARGX opened at $623.11 on Friday. The company has a market cap of $37.62 billion, a P/E ratio of -708.08 and a beta of 0.59. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $630.00. The firm’s 50 day moving average price is $574.53 and its 200 day moving average price is $505.00.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the company earned ($1.25) earnings per share. Research analysts forecast that argenx SE will post 2.2 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.